Cost Utility of Inflammation-Targeted Therapy for Patients With Ulcerative Colitis

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 10, 2012, Pages 1143-1151

  Saini, Sameer D ^a,b   Waljee, Akbar K ^a,b   Higgins, Peter D R ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cost Effectiveness Analysis; Health Services Research; IBD; ICER

Indexed keywords

AZATHIOPRINE; CALGRANULIN; INFLIXIMAB; MESALAZINE;

ARTICLE; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; FECES; FECES ANALYSIS; HEALTH INSURANCE; HUMAN; MEDICAL DECISION MAKING; QUALITY OF LIFE; SIMULATION; TREATMENT DURATION; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; HEALTH CARE COSTS; HUMANS; INFLAMMATION; MESALAMINE; TREATMENT OUTCOME;

EID: 84866454642     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.05.003     Document Type: Article

References (48)

1. Muir A.J., Edwards L.J., Sanders L.L., et al. A prospective evaluation of health-related quality of life after ileal pouch anal anastomosis for ulcerative colitis. Am J Gastroenterol 2001, 96:1480-1485.
2. Sewell J.L., Yee H.F., Inadomi J.M. Hospitalizations are increasing among minority patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2010, 16:204-207.
3. Gibson T.B., Ng E., Ozminkowski R.J., et al. The direct and indirect cost burden of Crohn's disease and ulcerative colitis. J Occup Environ Med 2008, 50:1261-1272.
4. Sutherland L., Macdonald J.K. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006, CD000544.
5. Higgins P.D., Rubin D.T., Kaulback K., et al. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther 2009, 29:247-257.
6. Rubin D.T., Siegel C.A., Kane S.V., et al. Impact of ulcerative colitis from patients' and physicians' perspectives: results from the UC: NORMAL survey. Inflamm Bowel Dis 2009, 15:581-588.
7. Yen E.F., Kane S.V., Ladabaum U. Cost-effectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitis. Am J Gastroenterol 2008, 103:3094-3105.
8. Nielsen O.H. Sulfasalazine intolerance: a retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. Scand J Gastroenterol 1982, 17:389-393.
9. Kane S.V., Accortt N.A., Magowan S., et al. Predictors of persistence with 5-aminosalicylic acid therapy for ulcerative colitis. Aliment Pharmacol Ther 2009, 29:855-862.
10. Accessed March 16, 2011. http://www.shire.com/shireplc/uploads/report/10K2007.pdf.
11. Gisbert J.P., Bermejo F., Pérez-Calle J.L., et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009, 15:1190-1198.
12. Gisbert J.P., McNicholl A.G., Gomollon F. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflamm Bowel Dis 2009, 15:1746-1754.
13. Costa F., Mumolo M.G., Ceccarelli L., et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005, 54:364-368.
14. van Rheenen P.F., Van de Vijver E., Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010, 341:c3369.
15. Mao R., Xiao Y.L., Gao X., et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis 2012 Jan 11, [Epub ahead of print].
16. Saini S.D., Schoenfeld P., Vijan S. Surveillance colonoscopy is cost-effective for patients with adenomas who are at high risk of colorectal cancer. Gastroenterology 2010, 138:2292-2299.
17. Hayward R.A., Krumholz H.M., Zulman D.M., et al. Optimizing statin treatment for primary prevention of coronary artery disease. Ann Intern Med 2010, 152:69-77.
18. Laharie D., Bourreille A., Branche J., et al. Cyclosporin versus infliximab in severe acute ulcerative colitis refractory to intravenous steroids: a randomized trial. Gastroenterology 2011, 140:S-112.
19. Holubar S.D., Long K.H., Loftus E.V., et al. Long-term direct costs before and after proctocolectomy for ulcerative colitis: a population-based study in Olmsted County, Minnesota. Dis Colon Rectum 2009, 52:1815-1823.
20. Arias E. United States life tables, 2006. Natl Vital Stat Rep 2010, 58:1-40.
21. Timmer A., McDonald J.W., Macdonald J.K. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007, CD000478.
22. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
23. Marteau P., Probert C.S., Lindgren S., et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005, 54:960-965.
24. Faubion W.A., Loftus E.V., Harmsen W.S., et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001, 121:255-260.
25. Turner D., Walsh C.M., Steinhart A.H., et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007, 5:103-110.
26. Shibolet O., Regushevskaya E., Brezis M., et al. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005, CD004277.
27. Lawson M.M., Thomas A.G., Akobeng A.K. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006, 3. CD005112.
28. Seva-Pereira A., Franco A.O., de Magalhães A.F. Diagnostic value of fecal leukocytes in chronic bowel diseases. Sao Paulo Med J 1994, 112:504-506.
29. Schoepfer A.M., Trummler M., Seeholzer P., et al. Accuracy of four fecal assays in the diagnosis of colitis. Dis Colon Rectum 2007, 50:1697-1706.
30. Kaplan G.G., McCarthy E.P., Ayanian J.Z., et al. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology 2008, 134:680-687.
31. Red Book 2009, Thomson Healthcare, Inc, Chicago, IL.
32. Ollendorf D.A., Lidsky L. Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting. Am J Ther 2006, 13:502-506.
33. Agency for Healthcare Research and Quality, Healthcare Cost and Utilization Project (HCUP), Accessed March 1, 2011. http://hcupnet.ahrq.gov/.
34. Physician fee schedule lookup Centers for Medicare and Medicaid Services, Accessed March 1, 2011. http://www.cms.hhs.gov/PFSlookup/.
35. Loftus E.V., Friedman H.S., Delgado D.J., et al. Colectomy subtypes, follow-up surgical procedures, postsurgical complications, and medical charges among ulcerative colitis patients with private health insurance in the United States. Inflamm Bowel Dis 2009, 15:566-575.
36. Waljee A.K., Higgins P.D., Waljee J.F., et al. Perceived and actual quality of life with ulcerative colitis: a comparison of medically and surgically treated patients. Am J Gastroenterol 2011, 106:794-799.
37. McLeod R.S., Churchill D.N., Lock A.M., et al. Quality of life of patients with ulcerative colitis preoperatively and postoperatively. Gastroenterology 1991, 101:1307-1313.
38. Fryback D.G., Dasbach E.J., Klein R., et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993, 13:89-102.
39. Gold M.R. Cost-effectiveness in health and medicine 1996, Oxford University Press, Oxford, UK.
40. Gower-Rousseau C., Dauchet L., Vernier-Massouille G., et al. The natural history of pediatric ulcerative colitis: a population-based cohort study. Am J Gastroenterol 2009, 104:2080-2088.
41. Henriksen M., Jahnsen J., Lygren I., et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis 2006, 12:543-550.
42. Langholz E., Munkholm P., Davidsen M., et al. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994, 107:3-11.
43. Briggs A.H., Claxton K., Sculpher M.J. Decision modelling for health economic evaluation 2006, Oxford University Press, Oxford, UK.
44. Huicho L., Campos M., Rivera J., et al. Fecal screening tests in the approach to acute infectious diarrhea: a scientific overview. Pediatr Infect Dis J 1996, 15:486-494.
45. Zulman D.M., Vijan S., Omenn G.S., et al. The relative merits of population-based and targeted prevention strategies. Milbank Q 2008, 86:557-580.
46. Rubenstein J.H., Waljee A.K., Jeter J.M., et al. Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates. Am J Gastroenterol 2009, 104:2222-2232.
47. Rutter M., Saunders B., Wilkinson K., et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004, 126:451-459.
48. Bernstein C.N., Nugent Z., Blanchard J.F. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol 2011, 106:731-736.